Innate Pharma S.A. (IPHA)
| Previous close | 5.69 |
| Open | 5.75 |
| Bid | 5.52 x 900 |
| Ask | 5.61 x 1300 |
| Day's range | 5.55 - 5.75 |
| 52-week range | 3.02 - 11.95 |
| Volume | 84,636 |
| Avg. volume | 2,290,026 |
| Market cap | 447.411M |
| Beta (5Y monthly) | -0.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.14 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.90 |
- Business Wire
Number of Shares and Voting Rights of Innate Pharma as of October 1, 2021
MARSEILLE, France, October 15, 2021--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris:– IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at October 1, 2021:
- Globe Newswire
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021
MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: Total number of shares outstanding:79,294,402 ordinary shares 6,784
- Motley Fool
Here's Why Innate Pharma Stock Is Rocketing Higher Today
Shares of Innate Pharma (NASDAQ: IPHA), a clinical-stage biotechnology company, are rocketing higher in response to successful clinical-trial data for an experimental cancer drug called monalizumab. Monalizumab is currently in a phase 2 trial called Coast, in combination with Imfinzi from AstraZeneca (NASDAQ: AZN). Imfinzi is approved to treat advanced-stage non-small cell lung cancer (NSCLC) patients with tumors that haven't grown since beginning standard first-line treatment.
